WELWYN GARDEN CITY, England and BOSTON, March 15, 2012 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, announces that its Chief Business Officer, Barry Kenny, will present overview of the Company at 09:45am CET on Tuesday20 March 2012 at the 6th Annual BIO-Europe Spring international partnering conference. The presentation will take place in room E107, Level 1.
BIO-Europe Spring, which is produced by EBD Group, is taking place at the Amsterdam RAI Convention Center in Amsterdam, the Netherlands on 19-21 March 2012.
About Heptares Therapeutics
Heptares discovers and develops new medicines targeting GPCRs (G-protein-coupled receptors), a super-family of drug targets linked to a wide range of human diseases. We have established R&D collaborations with Shire, Takeda, AstraZeneca, MedImmune and Novartis Option Fund, and have raised $40M in venture financing from MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. Heptares is an industry pioneer in GPCR structure-based drug design and has built a unique capability for discovering novel molecules that modulate historically un-druggable or challenging GPCRs. Our integrated discovery platform includes proprietary technologies for engineering stabilised GPCRs in their natural pharmacological conformations, identifying previously unknown chemistries for GPCR protein-drug interactions, and deploying advanced fragment-based approaches to GPCR target space for the first time. Using this approach, we are generating a broad pipeline of drug candidates for serious CNS and metabolic disorders, including Alzheimer's disease, Parkinson's disease, anxiety, chronic insomnia, addiction and diabetes. For more information, please visit http://www.heptares.com.
Citigate Dewe Rogerson
Mark Swallow, Chris Gardner
Heptares Therapeutics Ltd
Malcolm Weir, Chief Executive Officer (UK)
Dan Grau, President (USA)
SOURCE Heptares Therapeutics